Early medical studies have shown that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (angiotensin II receptor blockers) as first-line treatment for DN can reduce proteinuria, The role of delaying the progress of renal dysfunction.[7] However, the side effects of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers limit the use of these drugs. This evidence concerns the gene ACE and liver dysplastic nodule.